KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Deferred Revenue: 2010-2017

Historic Current Deferred Revenue for Pacira BioSciences (PCRX) over the last 8 years, with Dec 2017 value amounting to $102,000.

  • Pacira BioSciences' Current Deferred Revenue fell 82.86% to $102,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $102,000, marking a year-over-year decrease of 82.86%. This contributed to the annual value of $102,000 for FY2017, which is 82.86% down from last year.
  • Per Pacira BioSciences' latest filing, its Current Deferred Revenue stood at $102,000 for FY2017, which was down 82.86% from $595,000 recorded in FY2016.
  • Pacira BioSciences' Current Deferred Revenue's 5-year high stood at $1.4 million during FY2014, with a 5-year trough of $102,000 in FY2017.
  • Over the past 3 years, Pacira BioSciences' median Current Deferred Revenue value was $595,000 (recorded in 2016), while the average stood at $707,667.
  • Per our database at Business Quant, Pacira BioSciences' Current Deferred Revenue spiked by 41.47% in 2014 and then crashed by 82.86% in 2017.
  • Pacira BioSciences' Current Deferred Revenue (Yearly) stood at $1.0 million in 2013, then skyrocketed by 41.47% to $1.4 million in 2014, then remained steady at $1.4 million in 2015, then plummeted by 58.27% to $595,000 in 2016, then slumped by 82.86% to $102,000 in 2017.